Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 2 3Phase EARLY_PHASE1 2Phase 1 2Phase NA 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 45Uterine Cervical Neoplasms 24Endometrial Neoplasms 24Fallopian Tube Neoplasms 18Breast Neoplasms 13Pancreatic Neoplasms 7Carcinoma, Ovarian Epithelial 7Uterine Cervical Dysplasia 6Sarcoma 6Lung Neoplasms 6Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 5Colonic Neoplasms 5Stomach Neoplasms 4Melanoma 4Head and Neck Neoplasms 4Brain Neoplasms 4Uterine Neoplasms 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Renal Cell 3Vulvar Neoplasms 2Urinary Bladder Neoplasms 2Turcot syndrome 2Triple Negative Breast Neoplasms 2Recurrence 2Rectal Neoplasms 2Peritoneal Neoplasms 2

Interventions

tislelizumab 1Taxes 1Paclitaxel 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Turcot syndrome × Gynecologic × Clear all
NCT06305962 2026-02-19

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Radiopharm Theranostics, Ltd

Phase EARLY_PHASE1 Recruiting
30 enrolled
BreastDermatologicGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
2 enrolled
GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡